Managing post-bariatric weight recurrence with new obesity management medications
- Journal
- Nature reviews. Endocrinology (Q1)
- Published
- 19 November 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Davide Masi, Francesco De Domenico, Valeria Zanghi Buffi, Rossella Tozzi, Valentina Cipriani, Ludovico Di Gioia, et al.
- PMID
- 43058312
- DOI
- 10.1038/s41574-026-01324-y
Why clinicians should know about it
- Picked for Bariatric and Metabolic Surgery (paper of the day, 22 November 2026): Post-bariatric weight recurrence and medication, endoscopic, surgical options
Abstract
Recurrent weight gain (RWG) following metabolic and bariatric surgery (MBS) represents a major challenge in the long-term management of obesity and is distinct from insufficient weight loss and suboptimal clinical response, which reflect a primary inadequate response. RWG is defined as regain of ≥25% of the maximum weight lost, assessed ≥24 months after surgery. It affects approximately 35% of patients within 5 years of sleeve gastrectomy and approximately 15% within 5 years after Roux-en-Y gastric bypass. With longer follow-up, the number of affected patients rises to about one-third. RWG is multifactorial: genetic predisposition, preoperative metabolic phenotype, inadequate or failed surgical anatomy, and neurohormonal and adipose tissue adaptations interact over time to cause it, and no single variable accounts for it. Randomized evidence indicates that the operation itself is a determinant of long-term response: Roux-en-Y gastric bypass elicits greater postprandial GLP1 secretion, more durable weight loss and higher rates of type 2 diabetes mellitus remission than sleeve gastrectomy, so procedure selection warrants as much attention as postoperative management. Treatment should therefore be specific to phenotype and procedure, escalating from lifestyle optimization to obesity management medications, endoscopic revision and revisional surgery, if needed. Randomized data now support semaglutide after MBS, whereas evidence for tirzepatide, combined endoscopic-pharmacological strategies, or treatment sequencing remains observational and real-world adherence is a major constraint. Multimodal, integrated approaches combining behavioural, pharmacological and surgical strategies could help to improve treatment strategies for patients who experience RWG. This Review discusses the factors that contribute to RWG after MBS, considerations for clinical management of RWG, and questions that future research should aim to address to improve and maintain weight loss and other clinical outcomes after MBS. The Review also discusses clinical approaches to insufficient weight loss and suboptimal clinical response after MBS.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.